
    
      Patients with chronic refractory ITP are eligible for a 6- to 12-week therapeutic trial.
      After 24 months of treatment, patients who continue to demonstrate a sustained response, in
      the investigator's judgment, will be offered the opportunity to receive ongoing therapy.
    
  